Efficacy of gamma knife radiosurgery in brain metastases of primary gynecological tumors

Sadik, Zjiwar H A; Beerepoot, Laurens V.; Hanssens, Patrick

doi:10.1007/s11060-019-03094-2

Cited by 6 publications

(6 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We also observed that only case reports, case series, and retrospective database studies provided information on number of patients, incidence rates, clinicopathological features, symptoms, and types of treatments. After screening the titles and abstracts, 83 full texts on BMs from CC and 78 full texts on BM from EC were selected and summarized (Table 1 and Table S1 [9,, Table 2 and Table S2 [6,9,20,28,31,37,40,41,46,49,53,55,59,62,63,[66][67][68][69][70][71][72][73][74][75][77][78][79]81,82,84,). Several case reports about the FIGO stage were lacking, and only histologic information was described.…”

Section: Resultsmentioning

confidence: 99%

“…The survival of BMs from EC is very poor, and depends on the status of the primary lesion, the presence of extracranial metastases, and the volume, number, and site of metastases in the brain parenchyma. The survival time after diagnosis of BMs from EC was available for 946 patients in the literature and ranged from 0.1 to 171 months (median: 7.5 months) [ 6 , 9 , 28 , 31 , 37 , 40 , 41 , 46 , 49 , 53 , 55 , 59 , 62 , 63 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 77 , 78 , 79 , 81 , 82 , 84 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 ...…”

Section: Endometrial Cancermentioning

confidence: 99%

“…The survival of BMs from EC is very poor, and depends on the status of the primary lesion, the presence of extracranial metastases, and the volume, number, and site of metastases in the brain parenchyma. The survival time after diagnosis of BMs from EC was available for 946 patients in the literature and ranged from 0.1 to 171 months (median: 7.5 months) [6,9,28,31,37,40,41,46,49,53,55,59,62,63,[66][67][68][69][70][71][72][73][74][75][77][78][79]81,82,84,.…”

Section: Prognosismentioning

confidence: 99%

“…[6,9,28,31,37,40,41,46,49,53,55,59,62,63,[66][67][68][69][70][71][72][73][74][75][77][78][79]81,82,84,86…”

mentioning

confidence: 99%

See 3 more Smart Citations

Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato¹,

Tanase²,

Uno³

et al. 2021

Cancers

View full text Add to dashboard Cite

Reports on brain metastases (BMs) from uterine cervical carcinoma (CC) and uterine endometrial carcinoma (EC) have recently increased due to the development of massive databases and improvements in diagnostic procedures. This review separately investigates the prevalence, clinical characteristics, clinical presentation, diagnosis, treatment, and prognosis of BMs from CC and uterine endometrial carcinoma EC. For patients with CC, early-stage disease and poorly differentiated carcinoma lead to BMs, and elderly age, poor performance status, and multiple BMs are listed as poor prognostic factors. Advanced-stage disease and high-grade carcinoma are high-risk factors for BMs from EC, and multiple metastases and extracranial metastases, or unimodal therapies, are possibly factors indicating poor prognosis. There is no “most effective” therapy that has gained consensus for the treatment of BMs. Treatment decisions are based on clinical status, number of the metastases, tumor size, and metastases at distant organs. Surgical resection followed by adjuvant radiotherapy appears to be the best treatment approach to date. Stereotactic ablative radiation therapy has been increasingly associated with good outcomes in preserving cognitive functions. Despite treatment, patients died within 1 year after the BM diagnosis. BMs from uterine cancer remain quite rare, and the current evidence is limited; thus, further studies are needed.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Endometrial Cancermentioning

confidence: 99%

“…The survival of BMs from EC is very poor, and depends on the status of the primary lesion, the presence of extracranial metastases, and the volume, number, and site of metastases in the brain parenchyma. The survival time after diagnosis of BMs from EC was available for 946 patients in the literature and ranged from 0.1 to 171 months (median: 7.5 months) [6,9,28,31,37,40,41,46,49,53,55,59,62,63,[66][67][68][69][70][71][72][73][74][75][77][78][79]81,82,84,.…”

Section: Prognosismentioning

confidence: 99%

“…[6,9,28,31,37,40,41,46,49,53,55,59,62,63,[66][67][68][69][70][71][72][73][74][75][77][78][79]81,82,84,86…”

mentioning

confidence: 99%

See 2 more Smart Citations

Brain Metastases from Uterine Cervical and Endometrial Cancer

Kato¹,

Tanase²,

Uno³

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Some BMs remissions have been achieved in patients undergoing platinum-based regimen, with or without docetaxel, but these results remain anecdotal [15,[96][97][98][99]. In addition, in patients treated with exclusive systemic chemotherapy, the median survival remains poor (2.5 to 7 months) [100]. As mentioned above, the prognostic role for BMs of previous platinum sensitivity is not yet defined, however, this aspect must be considered when attempting a re-challenge with platinum-based chemotherapy.…”

Section: Chemotherapy With Cytotoxic Agentsmentioning

confidence: 99%

Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis

Borella

Bertero

Morrone

et al. 2020

Cancers

View full text Add to dashboard Cite

With this review, we provide the state of the art concerning brain metastases (BMs) from ovarian cancer (OC), a rare condition. Clinical, pathological, and molecular features, treatment options, and future perspectives are comprehensively discussed. Overall, a diagnosis of high-grade serous OC and an advanced disease stage are common features among patients who develop brain metastases. BRCA1 and BRCA2 gene mutations, as well as the expression of androgen receptors in the primary tumor, are emerging risk and prognostic factors which could allow one to identify categories of patients at greater risk of BMs, who could benefit from a tailored follow-up. Based on present data, a multidisciplinary approach combining surgery, radiotherapy, and chemotherapy seem to be the best approach for patients with good performance status, although the median overall survival (<1 year) remains largely disappointing. Hopefully, novel therapeutic avenues are being explored, like PARP inhibitors and immunotherapy, based on our improved knowledge regarding tumor biology, but further investigation is warranted.

show abstract